Floatz logo

BKM120

Selected Solid Tumors

Array Biopharma, now a wholly owned subsidiary of PfizerSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Selected Solid Tumors cohort.

Asset / SponsorPhaseRating
Binimetinib
Array Biopharma, now a wholly owned subsidiary of Pfizer
Phase 1CC

Same molecule, other indications

BKM120 is also rated in:

HER2 positive breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →
breast cancerDormant
B
Indicative ·
62 / 100
View asset →
glioblastomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →